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Chemotherapy is a relatively recent discipline, having its origins in
the 1970s, but its success can already be seen in the United Kingdom
and across the world. The initial advances, in terms of effective
disease management and improved outcomes, were seen in haemato-
logical malignancies, and were closely followed by improvements for
patients with breast cancer and other solid tumours.
In this supplement, Verrill highlights the increasing use of
intensive adjuvant regimens for breast cancer, and the increased
rates of febrile neutropenia (FN) associated with these regimens.
Development of FN can lead to morbidity, and indeed mortality,
for individual patients, and direct costs for the NHS, related to
hospital admission and treatment.
Yet neutropenia is often avoidable. One approach, if a
patient develops an episode of FN during chemotherapy, is dose
reduction during subsequent cycles. However, as Leonard has
pointed out (Leonard et al, 2003), compromising the dose of
chemotherapy in adjuvant treatment of breast cancer may also
compromise efficacy.
The National Confidential Enquiry into Patient Outcome and
Death (NCEPOD) report into deaths within 30 days of chemother-
apy reported that FN was a significant cause of iatrogenic death,
and that the standards of care for patients receiving chemotherapy
left considerable room for improvement (NCEPOD, 2008). These
findings were taken up by the National Chemotherapy Advisory
Group (NCAG), which made recommendations for the manage-
ment of chemotherapy-induced FN with the aim of improving
safety and outcome (NCAG, 2009).
These recommendations are extremely important, but can we do
more to prevent FN? The use of haematopoietic growth factors will
reduce the incidence of both asymptomatic neutropenia and FN
(Aapro et al, 2006; Smith et al, 2006), but it is not practical or cost-
effective to provide primary prophylaxis for all patients under-
going chemotherapy. As part of the European Union, maybe it is
time for the United Kingdom to consider an approach based
on the European guidelines for FN prevention (Aapro et al, 2006).
Under these guidelines, patients undergoing chemotherapy are
triaged for consideration of primary prophylaxis with growth
factors according to the intensity of the regimen and patient-
specific risk factors.
In an era when we have the ability to cure more patients and
prolong high-quality life for those we cannot cure, it beholds us to
make sure that our treatment does not create unnecessary
morbidity and mortality.
The articles in this supplement consider the burdens imposed by
FN, and the strategies available for preventing as well as providing
optimum management for this common side effect of many
chemotherapy regimens.
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